As you read the news reports on a new anti-viral pill to battle COVID-19 from Merck called “Molnupiravir”, keep in mind Merck is the pharma company the anti-viral pill Ivermectin.
– Positive clinical trial results for Merck & Co’s experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker’s stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Merck shares jumped as much as 12.3% and hit their highest level since February 2020 after could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19. Experts hailed the news as potentially a huge advance in the fight against COVID-19.
[…] “We see molnupiravir, with its oral format as a clear game changer that is likely to meaningfully impact not just the treatment paradigm for COVID-19 but also has potential utility in the prevention setting,” Piper Sandler analyst Christopher Raymond said in a research note.
Merck is conducting a late-stage trial to see if its antiviral pill can prevent COVID-19 infection, in addition to the study that showed it can significantly cut hospitalization and death in those already infected. Suspicious cat remains, well, suspicious…